Although single-agent immune checkpoint inhibitor (ICI) therapy with monoclonal antibodies targeting CTLA-4 and PD-1 has been the standard of care for patients with metastatic melanoma, the majority of patients did not experience long-term benefits from ICI monotherapy. The gene discussed is PDCD1; the disease is metastatic melanoma.